Zotarolimus-eluting stent in-stent restenosis

Original title: Clinical Outcomes of the Resolute Zotarolimus-Eluting Stent in Patients With In-Stent Restenosis Two-Year Results From a Pooled Analysis. Reference: Gert Richardt et al. J Am Coll Cardiol Intv 2013, article in press. Previous studies reported a target lesion revascularization (TLR) of 15% and target vessel (TVR) of 22%  after a year of treating an injury-stent restenosis.<a href="https://solaci.org/en/2013/08/16/zotarolimus-eluting-stent-in-stent-restenosis/" title="Read more" >...</a>

Multislice computed tomography for bioresorbable scaffolds: the end of invasive diagnostic studies?

Original title: Multislice Computed Tomography Angiography for Non-invasive Assessment of the 18-Months Performance of a Novel Radiolucent Bioresorbable Vascular Scaffolding Device (ABSORB Trial). Reference: Koen Nieman et al. J Am Coll Cardiol, article in press. Metal stents revolutionized coronary angioplasty procedures; however, they are permanent prosthetic devices that make re intervention difficult and prolongue thrombosis risk. This problem<a href="https://solaci.org/en/2013/08/14/multislice-computed-tomography-for-bioresorbable-scaffolds-the-end-of-invasive-diagnostic-studies/" title="Read more" >...</a>

Pharmacological stent intimal coverage with overlap versus no overlap

Original title: Tissue coverage and neointimal hyperplasia in overlap versus nonoverlap segments of drug-eluting stents 9 to 13 months after implantation: In vivo assessment with optical coherence tomography. Reference: Juan Luis Gutiérrez-Chico et al. Am Heart J 2013;166:83-94.e3. The drug-eluting stent’s (DES) overlapping effect over neointimal healing is not completely understood. Drug overdose, large amounts of polymer and<a href="https://solaci.org/en/2013/08/05/pharmacological-stent-intimal-coverage-with-overlap-versus-no-overlap/" title="Read more" >...</a>

Pulmonary denervation in primary pulmonary hypertension. First study in humans.

Original title: Pulmonary artery denervation to treat pulmonary arterial hypertension: a single center, prospective, first-in-man PADN-1 study. Reference: Shao-Liang Chen et al. J Am Coll Cardiol. Article in press. Idiopathic pulmonary hypertension is characterized by elevated mean pressure and resistance due to an imbalance between local vasodilator and vasoconstrictor added to the vascular wall renovation. Based on animal<a href="https://solaci.org/en/2013/07/18/pulmonary-denervation-in-primary-pulmonary-hypertension-first-study-in-humans/" title="Read more" >...</a>

Percutaneous Left Atrial Appendage Closure With the AMPLATZER : a valid alternative when anticoagulation is contraindicated

Original title: Percutaneous Left Atrial Appendage Closure With the AMPLATZER Cardiac Plug Device in Patients With Nonvalvular Atrial Fibrillation and Contraindication to Anticoagulation Therapy Reference: Marina Urena, et al. J Am Coll Cardiol 2013:62:96-102.   Anticoagulation is a good therapeutic strategy in nonvascular atrial fibrillation (AF). However, it is contraindicated in approximately 10% of patients, due to the<a href="https://solaci.org/en/2013/07/10/percutaneous-left-atrial-appendage-closure-with-the-amplatzer-a-valid-alternative-when-anticoagulation-is-contraindicated/" title="Read more" >...</a>

DES versus Bare in primary angioplasty at five years. Initial advantage is reducing

Original: title Long-Term Outcome After Drug-Eluting VersusBare-Metal Stent Implantation in Patients WithST-Segment Elevation Myocardial Infarction. 5 Years Follow-Up From the Randomized DEDICATION (Drug Elution and DistalProtection in Acute Myocardial Infarction) Trial. Reference: Lene Holmvang et al. J Am CollCardiolIntv 2013, article in press.   Primary angioplasty reduced mortality and reinfarction compared with thrombolytics in patients experiencing an ST<a href="https://solaci.org/en/2013/07/05/des-versus-bare-in-primary-angioplasty-at-five-years-initial-advantage-is-reducing/" title="Read more" >...</a>

Result of bifurcated devices to protect the internal iliac in aorto-iliac aneurysms

Original title: Endovascular Treatment of Aorto-iliac Aneurysms: Four-year Results of Iliac Branch Endograft. Reference: G. Pratesi et al. Eur J Vasc Endovasc Surg. 2013 Jun;45(6):607-9. Iliac bifurcated devices have proven to be effective in treating common iliac aneurysms but the findings are based on small series, generally from a sole center experience. This multicenter registry included 85 patients<a href="https://solaci.org/en/2013/06/30/result-of-bifurcated-devices-to-protect-the-internal-iliac-in-aorto-iliac-aneurysms/" title="Read more" >...</a>

Endovascular or surgical popliteal aneurysms exclusion – both with good results but for different patients.

Original title: A Multicentric Experience with Open Surgical Repair and Endovascular Exclusion of Popliteal Artery Aneurysms. Reference: R. Pulli et al. European Journal of Vascular and Endovascular Surgery, Volume 45, Issue 4, Pages 357-363.   Complications of a popliteal aneurysm may cause rupture, distal embolization or thrombosis with a risk of any of them affecting the lower limb.<a href="https://solaci.org/en/2013/06/26/endovascular-or-surgical-popliteal-aneurysms-exclusion-both-with-good-results-but-for-different-patients/" title="Read more" >...</a>

Self-expandable stenting with jailed deep femoral artery (DFA) for proximal superficial femoral artery (SFA) lesions is safe

Original title: Deployment of Self-Expandable Stents for Complex Proximal Superficial Femoral Artery Lesions Involving the Femoral Bifurcation With Or Without Jailed Deep Femoral Artery. Reference: Masahiro Yamawaki et al. Catheterization and Cardiovascular Interventions 81:1031–1041 (2013). The endovascular management of chronic total occlusions of the lower extremities has seen great progress over the past years; however, specific segments require<a href="https://solaci.org/en/2013/06/12/self-expandable-stenting-with-jailed-deep-femoral-artery-dfa-for-proximal-superficial-femoral-artery-sfa-lesions-is-safe/" title="Read more" >...</a>

Aspirin, Clopidogrel and Warfarin. Is it safe or is a triple scheme necessary?

Original title: Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Reference: Dewilde WJ et al. Lancet. 2013 Mar 30;381(9872):1107-15 The question to answer was simple, relevant, and is increasingly frequent in everyday practice: what to do when a patient who is anticoagulated has<a href="https://solaci.org/en/2013/05/10/aspirin-clopidogrel-and-warfarin-is-it-safe-or-is-a-triple-scheme-necessary/" title="Read more" >...</a>